Mission Pharmacal begins promotion of Elestrin

SAN ANTONIO — Mission Pharmacal on Thursday announced that it has begun the promotion of Elestrin (estradiol gel) 0.06% in the United States through an agreement with Meda AB. The drug is a used as a topical hormone replacement gel to help treat hot flashes caused by menopause.



The addition of Elestrin both complements and expands Mission Pharmacal's existing line of products for women, which includes such products as prescription prenatal vitamins, a bone health product, anti-infectives, an iron supplement and a urinary analgesic.



"Mission Pharmacal's commitment to women's health has never been stronger," said Dan Kibbe, SVP pharmaceutical division at Mission Pharmacal. "The addition of Elestrin further enhances our position as one of the most valuable partners in providing healthcare solutions for obstetricians and gynecologists (OB/GYNs) and their patients in the women's healthcare community."



Elestrin has been available by prescription in the United States since 2006.